Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

SER

Serina Therapeutics Inc.

Apr 24 • 04:00PM ET

10.00

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • AMEX

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-13.72	Insider Own	85.86%	Shs Outstand	1.08M	Perf Week	-17.36%
Market Cap	25.00M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.35M	Perf Month	-24.76%
Income	-14.80M	PEG	-	EPS next Q	-	Inst Own	5.76%	Short Float	1.56%	Perf Quarter	-30.65%
Sales	0.14M	P/S	178.57	EPS this Y	-	Inst Trans	-9.67%	Short Ratio	1.02	Perf Half Y	-56.39%
Book/sh	5.07	P/B	1.97	EPS next Y	-	ROA	-194.70%	Short Interest	0.01M	Perf Year	-54.87%
Cash/sh	0.14	P/C	73.53	EPS next 5Y	-	ROE	-	52W Range	9.71 - 35.17	Perf YTD	-26.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-12.67%	ROI	-240.23%	52W High	-71.57%	Beta	1.22
Dividend TTM	-	Quick Ratio	0.13	Sales past 5Y	-39.80%	Gross Margin	-20.42%	52W Low	2.99%	ATR (14)	1.43
Dividend Ex-Date	-	Current Ratio	0.13	EPS Y/Y TTM	-41.47%	Oper. Margin	-7014.08%	RSI (14)	40.87	Volatility	4.91% 10.53%
Employees	4	Debt/Eq	0.80	Sales Y/Y TTM	317.65%	Profit Margin	-10424.65%	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.13	EPS Q/Q	-27.85%	Payout	-	Rel Volume	0.06	Prev Close	10.00
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	600.00%	Earnings	-	Avg Volume	5.34K	Price	10.00
SMA20	-13.25%	SMA50	-23.45%	SMA200	-47.25%	Trades		Volume	332	Change	0.00%

Apr-17-24 04:05PM	Serina Therapeutics Appoints Dr. Simba Gill as Executive Chairman (GlobeNewswire)
Mar-26-24 05:04PM	Serina Therapeutics Announces Completion of Merger with AgeX Therapeutics (GlobeNewswire) -11.90%

Serina Therapeutics, Inc. operates as a pharmaceutical company, which engages in the development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SER

Serina Therapeutics Inc.

Upgrade your FINVIZ experience